This is an in-service training for staff of CUHK Medical Centre

Upon completion of the activity, participants will learn:

• the important role of pharmacovigilance by revisiting the thalidomide tragedy and recognizing public health commitments
• the key objectives of the Pregnancy Prevention Program (PPP) for Revlimid® (lenalidomide) & Pomalyst®(pomalidomide)
• the local implementation requirements for PPP to ensure the safe use of both products, in line with the Product Inserts
• the operation of i-access® online platform for PPP, streamlining the operational process
• Other risks of immunomodulatory agents in addition to teratogenicity